Although the endocannabinoid system (ECS) is involved in the regulation of several physiological processes, including sleep and the immune response, its role during infections has not been fully studied. It is well known that the use of this drug increases susceptibility to infections because of the impact on the modulation of the immune system. Concerning the medicinal or recreational use of marijuana, its influence on the course of an infection, whether this has been caused by bacteria, viruses, parasites, and to a lesser degree, fungi, has been reported. Furthermore, there is evidence suggesting the involvement of the ECS in the control and elimination of infectious agents such as bacteria, viruses, and some protozoa; in the case of fungi, few studies are available so far. The purpose of this review is to present the existing studies related to infections and the ECS, the microbicidal effects of compounds isolated from Cannabis sativa, and the association between marijuana use and the development of rare pathologies in specific diseases.

Keywords:
Endocannabinoids, Infections, Virus, Bacteria, Parasites
1.
Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232:54-61.
2.
Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA: International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010;62:588-631.
3.
Radwan MM, Ross SA, Slade D, Ahmed SA, Zulfiqar F, ElSohly MA: Isolation and characterization of new cannabis constituents from a high potency variety. Planta Med 2008;74:267-272.
4.
Radwan MM, ElSohly MA, El-Alfy AT, Ahmed SA, Slade D, Husni AS, Manly SP, Wilson L, Seale S, Cutler SJ, Ross SA: Isolation and pharmacological evaluation of minor cannabinoids from high-potency Cannabis sativa. J Nat Prod 2015;78:1271-1276.
5.
Gaoni Y, Mechoulam R: Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-1647.
6.
Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM: Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod 2008;71:1427-1430.
7.
Hanus LO: Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev 2009;29:213-271.
8.
Pertwee RG: Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol 2015;231:1-37.
9.
Cascio MG, Marini P: Biosynthesis and fate of endocannabinoids. Handb Exp Pharmacol 2015;231:39-58.
10.
Oddi S, Fezza F, Pasquariello N, De Simone C, Rapino C, Dainese E, Finazzi-Agrò A, Maccarrone M: Evidence for the intracellular accumulation of anandamide in adiposomes. Cell Mol Life Sci 2008;65:840-850.
11.
Turcotte C, Chouinard F, Lefebvre JS, Flamand N: Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol 2015;97:1049-1070.
12.
Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, Blau H, Mechoulam R: Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a “CB3” receptor. Eur J Pharmacol 2003;461:27-34.
13.
Irving A, Abdulrazzaq G, Chan SLF, Penman J, Harvey J, Alexander SPH: Cannabinoid receptor-related orphan G protein-coupled receptors. Adv Pharmacol 2017;80:223-247.
14.
Howlett AC, Shim JY: Cannabinoid receptors and signal transduction. Madame Curie Bioscience Database (Internet). Austin, Landes Bioscience, pp 2000-2013.
15.
Pertwee RG: Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008;13:147-159.
16.
Hu SS, Mackie K: Distribution of the endocannabinoid system in the central nervous system. Handb Exp Pharmacol 2015;231:59-93.
17.
Pertwee RG, Ross RA: Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002;66:101-121.
18.
Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65.
19.
Scott DA, Wright CE, Angus JA: Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 2004;109:124-131.
20.
Cui JH, Kim WM, Lee HG, Kim YO, Kim CM, Yoon MH: Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model. Neurosci Lett 2011;493:67-71.
21.
Burgos E, Gómez-Nicola D, Pascual D, Martín MI, Nieto-Sampedro M, Goicoechea C: Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. Eur J Pharmacol 2012;682:62-72.
22.
Merroun I, El Mlili N, Martinez R, Porres JM, Llopis J, Ahabrach H, Aranda P, Sanchez Gonzalez C, Errami M, Lopez-Jurado M: Interaction between orexin A and cannabinoid system in the lateral hypothalamus of rats and effects of subchronic intraperitoneal administration of cannabinoid receptor inverse agonist on food intake and the nutritive utilization of protein. J Physiol Pharmacol 2015;66:181-190.
23.
Alexander SP: Therapeutic potential of cannabis-related drugs. Prog Neuropsychopharmacol Biol Psychiatry 2016;4:157-166.
24.
McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS: Delta-(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 2002;302:451-465.
25.
Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P: Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 2010;215:598-605.
26.
Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, et al: Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nat Commun 2017;8:13958.
27.
Anday JK, Mercier RW: Gene ancestry of the cannabinoid receptor family. Pharmacol Res 2005;52:463-466.
28.
Elphick MR: BfCBR: a cannabinoid receptor ortholog in the cephalochordate Branchiostoma floridae (amphioxus). Gene 2007;399:65-71.
29.
Bradley SG, Munson AE, Dewey WL, Harris LS: Enhanced susceptibility of mice to combinations of delta 9-tetrahydrocannabinol and live or killed gram-negative bacteria. Infect Immun 1977;17:325-329.
30.
Wasim K, Haq I, Ashraf M: Antimicrobial studies of the leaf of Cannabis sativa L. Pak J Pharm Sci 1995;8:29-38.
31.
Nissen L, Zatta A, Stefanini I, Grandi S, Sgorbati B, Biavati B, Monti A: Characterization and antimicrobial activity of essential oils of industrial hemp varieties (Cannabis sativa L.). Fitoterapia 2010;81:413-419.
32.
Duncan M, Galic MA, Wang A, Chambers AP, McCafferty DM, McKay DM, Sharkey KA, Pittman QJ: Cannabinoid 1 receptors are critical for the innate immune response to TLR4 stimulation. Am J Physiol Regul Integr Comp Physiol 2013;305:224-231.
33.
Gui H, Sun Y, Luo ZM, Su DF, Dai SM, Liu X: Cannabinoid receptor 2 protects against acute experimental sepsis in mice. Mediators Inflamm 2013;2013:741303.
34.
Sardinha J, Kelly ME, Zhou J, Lehmann C: Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. Mediators Inflamm 2014;2014:978678.
35.
Kianian M, Al-Banna NA, Kelly ME, Lehmann C: Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut. J Basic Clin Physiol Pharmacol 2013;24:27-33.
36.
Huber GL, Pochay VE, Pereira W, Shea JW, Hinds WC, First MW, Sornberger GC: Marijuana, tetrahydrocannabinol, and pulmonary antibacterial defenses. Chest 1980;77:403-410.
37.
Ashfaq MK, Watson ES, elSohly HN: The effect of subacute marijuana smoke inhalation on experimentally induced dermonecrosis by S. aureus infection. Immunopharmacol Immunotoxicol 1987;9:319-331.
38.
Centers for Disease Control and Prevention: from 2013 (revised 15 November 2016). https://www.cdc.gov/legionella/index.html.
39.
Newton CA, Chou PJ, Perkins I, Klein TW: CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift to following immune activation by Legionella pneumophila infection. J Neuroimmune Pharmacol 2009;4:92-102.
40.
Klein TW, Cabral GA: Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol 2006;1:50-64.
41.
Lu T, Newton C, Perkins I, Friedman H, Klein TW: Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J Pharmacol Exp Ther 2006;319:269-276.
42.
Newton CA, Klein TW, Friedman H: Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta 9-tetrahydrocannabinol injection. Infect Immun 1994;62:4015-4020.
43.
Klein TW, Newton C, Widen R, Friedman H: Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Ther 1993;267:635-640.
44.
Smith MS, Yamamoto Y, Newton C, Friedman H, Klein T: Psychoactive cannabinoids increase mortality and alter acute phase cytokine responses in mice sublethally infected with Legionella pneumophila. Proc Soc Exp Biol Med 1997;214:69-75.
45.
Newton CA, Lu T, Nazian SJ, Perkins I, Friedman H, Klein TW: The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2. J Leukoc Biol 2004;76:854-861.
46.
Lu T, Newton C, Perkins I, Friedman H, Klein TW: Role of cannabinoid receptors in delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila. Eur J Pharmacol 2006;532:170-177.
47.
Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA: Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen presenting cells. Cell 2004;117:515-526.
48.
Klein TW, Newton CA, Nakachi N, Friedman H: Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 2000;164:6461-6466.
49.
Morahan PS, Klykken PC, Smith SH, Harris LS, Munson AE: Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infect Immun 1979;23:670-674.
50.
Hischebeth GT, Keil VC, Gentil K, Boström A, Kuchelmeister K, Bekeredjian-Ding I: Rapid brain death caused by cerebellar abscess with Fusobacterium nucleatum in a young man with drug abuse: a case report. BMC Res Notes 2014;7:353.
51.
Gross A, Terraza A, Marchant J, Bouaboula M, Ouahrani-Bettache S, Liautard JP, Casellas P, Dornand J: A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis. J Leukoc Biol 2000;67:335-344.
52.
Gross A, Bouaboula M, Casellas P, Liautard JP, Dornand J: Subversion and utilization of the host cell cyclic adenosine 5'-monophosphate/protein kinase A pathway by Brucella during macrophage infection. J Immunol 2003;170:5607-5614.
53.
WHO: World Health Organization, Geneva, Switzerland, from 2015 (revised November 2016 and May 2017). http://www.who.int/en/.
54.
Bass R, Engelhard D, Trembovler V, Shohami E: A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. J Infect Dis 1996;173:735-738.
55.
Barichello T, Ceretta RA, Generoso JS, Moreira AP, Simões LR, Comim CM, Quevedo J, Vilela MC, Zuardi AW, Crippa JA, Teixeira AL: Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. Eur J Pharmacol 2012;697:158-1564.
56.
Sylvestre DL, Clements BJ, Malibu Y: Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol 2006;18:1057-1063.
57.
Costiniuk CT, Mills E, Cooper CL: Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol 2008;22:376-380.
58.
Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A: Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63-71.
59.
Sun LJ, Yu JW, Wan L, Zhang XY, Shi YG, Chen MY: Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. Int J Infect Dis 2014;23:75-81.
60.
Cabral GA, McNerney PJ, Mishkin EM: Delta-9-tetrahydrocannabinol enhances release of herpes simplex virus type 2. J Gen Virol 1986;67(Pt 9):2017-2022.
61.
Cabral GA, McNerney PJ, Mishkin EM: Effect of micromolar concentrations of delta-9-tetrahydrocannabinol on herpes simplex virus type 2 replication in vitro. J Toxicology Environ Health 1987;21:277-293.
62.
Mishkin EM, Cabral GA: Inhibition of cell-associated herpes simplex virus type 2 glycoproteins by delta 9-tetrahydrocannabinol. Proc Soc Exp Biol Med 1987;185:41-48.
63.
Cabral GA, Lockmuller JC, Mishkin EM: Delta 9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proc Soc Exp Biol Med 1986;181:305-311.
64.
Cabral GA, Vasquez R: Delta 9-tetrahydrocannabinol suppresses macrophage extrinsic antiherpesvirus activity. Proc Soc Exp Biol Med 1992;199:255-263.
65.
Mishkin EM, Cabral GA: Delta-9-tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. Gen Virol 1985;66:2539-2549.
66.
Cabral GA, Mishkin EM, Marciano-Cabral F, Coleman P, Harris L, Munson AE: Effect of delta 9-tetrahydrocannabinol on herpes simplex virus type 2 vaginal infection in the guinea pig. Proc Soc Exp Biol Med 1986;182:181-186.
67.
Maor Y, Yu J, Kuzontkoski PM, Dezube BJ, Zhang X, Groopman JE: Cannabidiol inhibits growth and induces programmed cell death in Kaposi sarcoma-associated herpesvirus-infected endothelium. Genes Cancer 2012;3:512-520.
68.
Ongrádi J, Specter S, Horváth A, Friedman H: Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells. Pathol Oncol Res 1998;4:191-199.
69.
Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC: Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci 2005;77:1711-1722.
70.
Purohit V, Rapaka RS, Rutter J: Cannabinoid receptor-2 and HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol 2014;9:447-453.
71.
Raborn ES, Jamerson M, Marciano-Cabral F, Cabral GA: Cannabinoid inhibits HIV-1 Tat-stimulated adhesion of human monocyte-like cells to extracellular matrix proteins. Life Sci 2014;104:15-23.
72.
Lombard C, Hegde VL, Nagarkatti M, Nagarkatti PS: Perinatal exposure to Δ-9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens. J Pharmacol Exp Ther 2011;339:607-617.
73.
Winsauer PJ, Molina PE, Amedee AM, Filipeanu CM, McGoey RR, Troxclair DA, Walker EM, Birke LL, Stouwe CV, Howard JM, Leonard ST, Moerschbaecher JM, Lewis PB: Tolerance to chronic delta-9-tetrahydrocannabinol (Δ9-THC) in rhesus macaques infected with simian immunodeficiency virus. Exp Clin Psychopharmacol 2011;19:154-172.
74.
Molina PE, Winsauer P, Zhang P, Walker E, Birke L, Amedee A, Stouwe CV, Troxclair D, McGoey R, Varner K, Byerley L, LaMotte L: Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Res Hum Retroviruses 2011;27:585-592.
75.
Amedee AM, Nichols WA, LeCapitaine NJ, Stouwe CV, Birke LL, Lacour N, Winsauer PJ, Molina PE: Chronic Δ-9-tetrahydrocannabinol administration may not attenuate simian immunodeficiency virus disease progression in female rhesus macaques. AIDS Res Hum Retroviruses 2014;30:1216-1225.
76.
Krishnan G, Chatterjee N: Endocannabinoids affect innate immunity of Müller glia during HIV-1 Tat cytotoxicity. Mol Cell Neurosci 2014;59:10-23.
77.
Buchweitz JP, Karmaus PW, Williams KJ, Harkema JR, Kaminski NE: Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of delta-9-tetrahydrocannabinol. J Leukoc Biol 2008;83:785-796.
78.
Buchweitz JP, Karmaus PW, Harkema JR, Williams KJ, Kaminski NE: Modulation of airway responses to influenza A/PR/8/34 by delta-9-tetrahydrocannabinol in C57BL/6 mice. J Pharmacol Exp Ther 2007;323:675-683.
79.
Karmaus PW, Chen W, Crawford R, Kaplan BL, Kaminski NE: Δ9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2. Toxicol Sci 2013;131:419-433.
80.
Mestre L, Docagne F, Correa F, Loría F, Hernangómez M, Borrell J, Guaza C: A cannabinoid agonist interferes with the progression of chronic model of multiple sclerosis by down regulating adhesion molecules. Mol Cell Neurosci 2009;40:258-266.
81.
Arevalo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C: Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003;23:2511-2516.
82.
Mestre L, Correa F, Docagne F, Clemente D, Guaza C: The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol 2006;72:869-880.
83.
Mestre L, Iñigo PM, Mecha M, Correa FG, Hernangómez-Herrero M, Loría F, Docagne F, Borrell J, Guaza C: Anandamide inhibits Theiler's virus-induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood-brain barrier by activation of CB1 receptors. J Neuroinflammation 2011:8:102.
84.
Mecha M, Feliú A, Iñigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C: Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. Neurobiol Dis 2013:59:141-150.
85.
Katona S, Kaminski E, Sanders H, Zajicek J: Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exp Immunol 2005;140:580-585.
86.
Arevalo-Martin A, Molina-Holgado E, Guaza C: A CB1/CB2 receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin. Neuropharmacology 2012;63:385e393.
87.
Kozela E, Juknat A, Kaushansky N, Rimmerman N, Ben-Nun A, Vogel Z: Cannabinoids decrease the Th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol 2013;8:1265-1276.
88.
Murphy AC, Lalor SJ, Lynch MA, Mills KH: Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 2010;24:641-651.
89.
McClean DK, Zimmerman AM: Action of delta 9-tetrahydrocannabinol on cell division and macromolecular synthesis in division-synchronized protozoa. Pharmacology 1976;14:307-321.
90.
Pringle HL, Bradley SG, Harris LS: Susceptibility of Naegleria fowleri to delta 9-tetrahydrocannabinol. Antimicrob Agents Chemother 1979;16:674-679.
91.
Dey R, Pernin P, Bodennec J: Endocannabinoids inhibit the growth of free-living amoebae. Antimicrob Agents Chemother 2010;54:3065-3067.
92.
Marciano-Cabral F, Ferguson T, Bradley SG, Cabral G: Delta-9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, exacerbates brain infection by Acanthamoeba. J Eukaryot Microbiol 2001;(suppl):4S-5S.
93.
Cabral GA, Marciano-Cabral F: Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J Neuroimmunol 2004;147:127-130.
94.
Marciano-Cabral F, Raborn ES, Martin BR, Cabral GA: Delta-9-tetrahydrocannabinol, the major psychoactive component in marijuana, inhibits macrophage chemotaxis to Acanthamoeba. J Eukaryot Microbiol 2006;53(suppl 1):S15-S17.
95.
Burnette-Curley D, Marciano-Cabral F, Fischer-Stenger K, Cabral GA: Delta-9-tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmétte-Guérin-activated macrophages. Int J Immunopharmacol 1993;15:371-382.
96.
Nok AJ, Ibrahim S, Arowosafe S, Longdet I, Ambrose A, Onyenekwe PC, Whong CZ: The trypanocidal effect of Cannabis sativa constituents in experimental animal trypanosomiasis. Vet Hum Toxicol 1994;36:522-524.
97.
Croxford JL, Wang K, Miller SD, Engman DM, Tyler KM: Effects of cannabinoid treatment on Chagas disease pathogenesis: balancing inhibition of parasite invasion and immunosuppression. Cell Microbiol 2005;7:1592-1602.
98.
Roulette CJ, Kazanji M, Breurec S, Hagen EH: High prevalence of cannabis use among Aka foragers of the Congo Basin and its possible relationship to helminthiasis. Am J Hum Biol 2016;28:5-15.
99.
Mukhtar T, Zameer Kayani M, Arshad Hussain M: Nematicidal activities of Cannabis sativa L. and Zanthoxylum alatum Roxb. against Meloidogyne incognita. Ind Crops Prod 2013;42:447-453.
100.
Campos AC, Brant F, Miranda AS, Machado FS, Teixeira AL: Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria. Neuroscience 2015;289:166-180.
101.
Alferink J, Specht S, Arends H, Schumak B, Schmidt K, Ruland C, et al: Cannabinoid receptor 2 modulates susceptibility to experimental cerebral malaria through a CCL17-dependent mechanism. J Biol Chem 2016;291:19517-19531.
102.
Liu H, Gao X, Duan R, Yang Q, Zhang Y, Cheng Y, Guo Y, Tang W: Endocannabinoids anandamide and its cannabinoid receptors in liver fibrosis after murine schistosomiasis. J Huazhong Univ Sci Technolog Med Sci 2009;29:182-186.
103.
Wang M, Abais JM, Meng N, Zhang Y, Ritter JK, Li PL, Tang WX: Upregulation of cannabinoid receptor-1 and fibrotic activation of mouse hepatic stellate cells during Schistosoma japonicum infection: role of NADPH oxidase. Free Radic Biol Med 2014;71:109-120.
104.
Darling MR, Arendorf TM, Coldrey NA: Effect of cannabis use on oral candidal carriage. J Oral Pathol Med 1990;19:319-321.
105.
Szyper-Kravitz M, Lang R, Manor Y, Lahav M: Early invasive pulmonary aspergillosis in a leukemia patient linked to Aspergillus- contaminated marijuana smoking. Leuk Lymphoma 2001;42:1433-1437.
106.
Hamadeh R, Ardehali A, Locksley RM, York MK: Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. Chest 1988;94:432-433.
107.
Ahmed SA, Ross SA, Slade D, Radwan MM, Zulfiqar F, Matsumoto RR, Xu YT, Viard E, Speth RC, Karamyan VT, ElSohly MA: Cannabinoid ester constituents from high-potency Cannabis sativa. J Nat Prod 2008;71:536-542.
108.
Blumstein GW, Parsa A, Park AK, McDowell BL, Arroyo-Mendoza M, Girguis M, Adler-Moore JP, Olson J, Buckley NE: Effect of delta-9-tetrahydrocannabinol on mouse resistance to systemic Candida albicans infection. PLoS One 2014;9.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.